Acute Myeloid Leukemia (original) (raw)
Latest News for: acute myeloid leukemia
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in ...
GetNews 13 Jun 2026
Inactive Products Relapsed/refractory acute myeloid leukemia (AML) Key Companies Relapsed/refractory acute myeloid leukemia (AML) Key Products Relapsed/refractory acute myeloid leukemia (AML)- Unmet ...
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Killeen Daily Herald 11 Jun 2026
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine ....
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress (ASEBIO - Asociación Española de Bioempresas)
Public Technologies 11 Jun 2026
[...]. This is an abstract of the document. To keep reading, click here and get access to the original version ... Disclaimer ... (noodl. 132416823) .
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (Form 6-K) (Evaxion A/S)
Public Technologies 11 Jun 2026
EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML).
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress (Oryzon Genomics SA)
Public Technologies 11 Jun 2026
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress ... leukemia (AML) patients (ALICE trial).
Acute Myeloid Leukemia Pipeline Shows Potential with Active Contributions from 100+ Key Companies | DelveInsight
GetNews 03 Jun 2026
Inactive Products Acute Myeloid Leukemia (AML) Key Companies Acute Myeloid Leukemia (AML) Key Products Acute Myeloid Leukemia (AML) – Unmet Needs Acute Myeloid Leukemia (AML) – Market ...
Acute Myeloid Leukemia - Hematology Clinical Case "Chase the Case" #56 (Horiba Ltd)
Public Technologies 15 May 2026
). Explore a real clinical case of Acute Myeloid Leukemia and discover how extended WBC differential parameters of the Yumizen H2500 hematology analyzer identified abnormal cell populations ... About Chase the Case ... Disclaimer. Horiba Ltd.
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
Nasdaq Globe Newswire 13 May 2026
... iadademstat in acute myeloid leukemia (AML) will be presented in two poster sessions at the European Hematology Association (EHA) Annual Congress, taking place June 11-14, 2026 in Stockholm, Sweden.
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026 (ASEBIO - Asociación Española de Bioempresas)
Public Technologies 13 May 2026
[...]. This is an abstract of the document. To keep reading, click here and get access to the original version ... Disclaimer ... (noodl. 131729328) .
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026 (Oryzon Genomics SA)
Public Technologies 13 May 2026
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026 ... Safety and Efficacy of Iadademstat Plus Gilteritinib in the FRIDA Expansion Cohort of FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, ...
Nasdaq Globe Newswire 12 May 2026
EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its ...
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress (Form 6-K) (Evaxion A/S)
Public Technologies 12 May 2026
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress Data will reflect the functional characterization of EVX-04 Poster presentation on June 13, 2026.
BCN HEALTH publishes a study evaluating the incidence, management, and associated costs of acute myeloid leukemia and myelodysplastic syndrome in Spain (ASEBIO - Asociación Española de Bioempresas)
Public Technologies 06 May 2026
... "Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level.
Acute Myeloid Leukemia Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for ...
GetNews 29 Apr 2026
Company Name Inactive Products Acute Myeloid Leukemia Key Companies Acute Myeloid Leukemia Key Products Acute Myeloid Leukemia - Unmet Needs Acute Myeloid Leukemia - Market Drivers and Barriers Acute ...
Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs ...
GetNews 23 Apr 2026
Inactive Products Relapsed/refractory acute myeloid leukemia (AML) Key Companies Relapsed/refractory acute myeloid leukemia (AML) Key Products Relapsed/refractory acute myeloid leukemia (AML)- Unmet ...